Figure 3.

Mutations identified in cfDNA from Hispanic patients with advanced fibrosis/cirrhosis. (A) cfDNA concentration in plasma of subjects with APRI < 1 and APRI ≥ 1. (B) Clinical parameters of all CCHC subjects. (C) Genomic landscape of cfDNA from patients with advanced fibrosis/cirrhosis. Heatmap illustrating nonsynonymous mutations detected in plasma. The upper bar charts represent the number of mutations in each patient. The right bars show the frequencies of specific altered genes in the total cohort. Data are presented as mean ± SEM. APRI, Aspartate transaminase to Platelet Ratio Index; Rs, spearman correlation coefficient; NFS, NAFLD Fibrosis Score; AST, aspartate transaminase; ALT, alanine transaminase; BMI, body mass index.